[Construction of the nucleic vaccine pVVP3L-18HN and its antitumor effect on human laryngeal carcinoma].
OBJECTIVE
Nucleic vaccine of pVVP3IL-18HN expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene were constructed to observe the combinative antitumor effect of the above three genes.


METHODS
Eukaryotic expression plasmid pVVP3IL-18HN was constructed by inserting apoptin gene and fragment comprising fused IL-18HN gene and IRES promoter into the downstream of CMV promoter of vector pVAX1. The expression of inserted gene was identified by RT-PCR, indirect immunofluorescence and Western-blot. The recombinant plasmid was introduced into Hep-2 cells by liposome, then suppression rate of Hep-2 of different time and different quantity was calculated according to MTT results.


RESULTS
The recombinant plasmid of pVVP3IL-18HN suppressed Hep-2 successfully and its suppression rate was up to 61.9% with 20 microg/ml, incubation of 72 hours.


CONCLUSIONS
The nucleic vaccine constructed pVVP3IL-18HN had antitumor effect on Hep-2. It may can be used to the therapy and research of laryngeal carcinoma.
Guan
Guo-fang
GF
Department of Otorhinolaryngology, The Second Hospital of Jilin University, Changchun 130041, China.
Jin
Ning-yi
NY
Mi
Zhi-qiang
ZQ
Li
Xiao
X
Lian
Hai
H
Jin
Chun-shun
CS
Sun
Li-li
LL
Wen
Lian-ji
LJ
D019496:Cancer Vaccines / Q000096:biosynthesis*; D015870:Gene Expression; D005822:Genetic Vectors; D015707:HN Protein / Q000235:genetics; D056945:Hep G2 Cells; D006801:Humans; D020382:Interleukin-18 / Q000235:genetics; D007822:Laryngeal Neoplasms / Q000276:immunology* / Q000517:prevention & control; D009522:Newcastle disease virus / Q000276:immunology; D010957:Plasmids; D014162:Transfection; D019444:Vaccines, DNA / Q000096:biosynthesis*
D019496:Cancer Vaccines; D015707:HN Protein; D020382:Interleukin-18; D019444:Vaccines, DNA